ESMO 2025 GU Industry Satellite Symposium
ESMO 2025 GU Industry Satellite Symposium
Featuring expert insights from Dr. Elena Castro, Prof. Dr. Axel Heidenreich, and Dr. Alejo Rodríguez-Vida on key considerations in GU care.
Catch up on our GU session below.
About this Session
The power of precision medicine: Transforming patient outcomes in GU oncology
Watch this expert panel discuss strategies for integrating early genetic testing into clinical practice and personalising treatment approaches for patients with prostate and bladder cancer.Learning Outcomes
- To integrate patient management considerations and personalised molecular strategies into clinical decision making for genitourinary (GU) cancer treatment
- To explore strategies for delivering patient-centred care in mHSPC, including the role of early biomarker and genomic testing, to improve clinical outcomes
- To shed light on treatment individualisation strategies based on patient-specific genetic alterations to improve patient outcomes in mUC
Watch the full symposium
Expert highlights
Optimising outcomes: Patient-centred care in mHSPC
Dr. Alejo Rodríguez-Vida explores optimising patient-centred care in mHSPC, including treatment personalisation and insights from recent clinical analyses.
Timely testing in prostate cancer: Addressing the unmet needs
Prof. Dr. Axel Heidenreich highlights the importance of early genomic testing to guide treatment decisions for patients with mHSPC and HRR mutations.
Session Agenda
| 18:00-18:05 | Welcome and introductions | Co-chairs: Elena Castro and Patrizia Giannatempo |
| 18:05-18:25 | Optimising outcomes: Patient-centred care in mHSPC | Alejo Rodríguez-Vida Discussant: Elena Castro |
| 18:25-18:45 | Timely testing in prostate cancer: Addressing the unmet needs | Axel Heidenreich Discussant: Elena Castro |
| 18:45-18:50 | Personalising an mUC patient’s journey: A case presentation | Patrizia Giannatempo Discussant: Enrique Grande |
| 18:50-19:00 | A guide to the guidelines: Strategies for mUC management | Enrique Grande |
| 19:00-19:10 | Navigating the treatment landscape at second-line to improve patient outcomes | Syed Hussain Discussant: Enrique Grande |
| 19:10-19:20 | Clinical compass for treatment individualisation in mUC management | Patrizia Giannatempo Discussant: Enrique Grande |
| 19:20-19:25 | Panel discussion | Patrizia Giannatempo and Syed Hussain; moderated by Enrique Grande |
| 19:25-19:30 | Final thoughts and closing | Co-chairs: Elena Castro and Patrizia Giannatempo |
The recorded content may not be available in your country. To request access to recordings and session materials, please contact our team.
Hear from the Experts
Dr. Elena Castro
Dr. Elena Castro discusses how genetic testing, treatment personalisation, and biomarker-driven strategies can address unmet needs in mHSPC while balancing rapid clinical advances with practical implementation challenges.
Prof. Dr. Axel Heidenreich
Prof. Dr. Axel Heidenreich addresses the role of molecular testing, emerging trial data, and strategies to advance personalised, patient-centred care across the prostate cancer journey.
Dr. Alejo Rodríguez-Vida
Dr. Alejo Rodríguez-Vida examines how emerging data and research can guide personalised treatment, address unmet needs, and shape the future of care for patients with mHSPC.
Past Events
If you registered for a previous session but were unable to attend, you can log in to access recorded sessions and request materials. Please note that for some recordings and materials, the content may not be available in your country.
UROonco 2025
(Bio) Markers and milestones at the crossroads of mHSPC
EMUC 2024
Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC
| ⓘ The recorded content may not be available in your country. To request access to recordings and session materials, please contact our team. |
Related Content
Centre of Excellence: BRCA testing
Advancing precision medicine in prostate cancer with the world-leading Gemelli Hospital
At this event, healthcare professionals from across the EMEA region came together to collaborate, exchange real-world insights, and advance evidence-based prostate cancer care in everyday clinical practice.
UROonco 2025
Our prostate cancer session – ‘(Bio) Markers and milestones at the crossroads of mHPSC’ – explored the latest developments and challenges in the field.
.png?width=408&height=230&format=webp&quality=60)
Introducing J&J withMe
A patient-centric platform designed to support patients throughout their healthcare journey. It provides personalised, high-quality content and services to enhance patient engagement.
By empowering informed, proactive patients, J&J withMe helps improve treatment outcomes.
Learn how this platform can strengthen your patient relationships — explore J&J withMe today!
Register with J&J Medical Cloud to access our full education library, including recordings, slides, and new session announcements.
Stay in Touch
Contact us
To report an Adverse Event (medication side effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
Abbreviations
BRCA, breast cancer gene; GU, genitourinary; HRR, homologous recombinant repair; mCRPC, metastatic castration resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; mUC, metastatic urothelial carcinoma.
CP-540415 - December 2025
Janssen Pharmaceutica NV